Drug Approval | March 02, 2022
Amneal enters U.S. biosimilars market with approval of Releukotm
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
Serina has over 17 years of experience in the biopharmaceutical industry
This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximizing value of data for drug discovery and precision medicine
Achieving ML 4 brings Singapore closer to becoming a WHO listed authority, a new scheme that will be operational later this year and will list the world’s regulators of reference
High level of vaccine efficacy maintained over a 6-month period of surveillance
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
This medicine was previously available in 40mg and 80mg strength, for which patients had to consume 2 tablets a day as per the approved dosage
The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
First-of-its-kind precision medicine test to predict a cancer patient’s response to an Immune Checkpoint Inhibitor (ICI)
Subscribe To Our Newsletter & Stay Updated
